Sarny Stephanie, Neumayer Michael, Kofler Julian, El-Shabrawi Yosuf
General Hospital Klagenfurt, Department of Opthalmology, Feschnigstraße 11, A-9020, Klagenfurt, Austria.
General Hospital Klagenfurt, Department of Dermatology, Feschnigstraße 11, A-9020, Klagenfurt, Austria.
BMC Ophthalmol. 2017 Aug 17;17(1):146. doi: 10.1186/s12886-017-0541-0.
To report a case of uveitis and neuroretinal detachment in a patient treated with Trametinib and Dabrafenib due to metastatic cutaneous melanoma stage IV.
We evaluated slit lamp examination, fundoscopy, optical coherence tomography, fluorescein and indocyanine green angiography in a 66 years old man suffering visual loss. Fundoscopy showed serous neuroretinal detachment of the fovea accompanied with white spots surrounding the fovea in both eyes. Although therapy with Trametinib and Dabrafenib was stopped uveitis anterior was seen 2 weeks later. After a year, the therapy was started again and the serous neuroretinal detachment appeared once more, however without inflammatory reaction of the anterior chamber.
Patients treated with Trametinib and Dabrafenib should undergo consecutive eye examinations from the beginning of the therapy.
报告一例因IV期转移性皮肤黑色素瘤接受曲美替尼和达拉非尼治疗的患者发生葡萄膜炎和神经视网膜脱离的病例。
我们对一名66岁视力丧失的男性进行了裂隙灯检查、眼底镜检查、光学相干断层扫描、荧光素和吲哚菁绿血管造影。眼底镜检查显示双眼黄斑区浆液性神经视网膜脱离，黄斑周围有白色斑点。尽管停用了曲美替尼和达拉非尼治疗，但2周后出现了前葡萄膜炎。一年后，再次开始治疗，浆液性神经视网膜脱离再次出现，但前房无炎症反应。
接受曲美替尼和达拉非尼治疗的患者应从治疗开始就进行连续的眼部检查。
